It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...
Taysha Gene Therapies has delivered a 90.1% gain over the past three years, which puts fresh attention on whether that kind ...
Beam Therapeutics sits in a crowded gene editing field, and its share price history raises a simple question for you as an investor: Is the current US$24.37 price properly reflecting what the business ...
Hosted on MSN
Morgan Stanley nearly doubled its price target for CRISPR Therapeutics. Is the gene-editing stock a no-brainer buy?
CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon. The stock is somewhat risky given the possibility of clinical failures. 10 stocks we ...
Japan's Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) is acquiring a 15% stake in Taysha Gene Therapies (NASDAQ:TSHA) for $50M to support the advancement of Taysha's gene therapy programs for Rett ...
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) announced that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR.
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results